Russell E. Madsen - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Russell E. Madsen


Russell E. Madsen is a Pharmtech editorial advisory board (EAB) member

Russell E. Madsen
President, The Williamsburg
Group, LLC

Russell E. Madsen is president of The Williamsburg Group, LLC, in Gaithersburg, Maryland, which is engaged in pharmaceutical consulting in the areas of CGMP compliance and auditing, quality systems, design review, aseptic processing and sterilization technology, sterile filtration, due diligence evaluation, process validation, regulatory liaison and general technical services.  Most recently, he had served PDA as acting president and was senior vice-president of science and technology, responsible for the overall scientific, technical and regulatory affairs activities of the association. 

Before joining PDA, he was employed by Bristol-Myers Squibb as director of technical services, providing technical and general consulting services to Bristol-Myers Squibb pharmaceutical, medical device, nutritional, and cosmetic operations worldwide. He currently is vice-chairman of ASTM E55.03 General Pharmaceutical Standards, serves as a member of the USP Parenteral Products-Industrial Expert Committee, is a member of Pharmaceutical Technology’s editorial advisory board, and is senior technical documents advisor to ISPE.  Madsen holds a BS from St. Lawrence University and a MS in Chemistry from Rensselaer Polytechnic Institute.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here